Abnormalities of retinoblastoma gene expression in hematological malignancies.

Abstract:

:The human retinoblastoma gene product which is involved in cell cycle control and also acts as a transcriptional repressor of genes involved in growth control, is constitutively expressed as a phosphoprotein in normal hemopoietic cells. Abnormalities of the retinoblastoma gene expression leading to loss of protein expression either due to structural changes, mutations or transcriptional abnormalities have been found in a variety of hematological malignancies. There is evidence that loss of Rb protein expression is particularly associated with tumour progression and an adverse response to therapy which may be linked to the biological effect of Rb protein loss on the growth characteristics of tumour cells.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Zhu YM,Haynes AP,Keith FJ,Russell NH

doi

10.3109/10428199509064923

subject

Has Abstract

pub_date

1995-06-01 00:00:00

pages

61-7

issue

1-2

eissn

1042-8194

issn

1029-2403

journal_volume

18

pub_type

杂志文章,评审
  • Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia.

    abstract::Rituximab (IDEC C2B8) is a chimeric human-mouse monoclonal anti-CD20 antibody that has been proven to be effective for the treatment of patients with CD20 positive leukemia and lymphoma. The level of CD20-expression in patients with B-cell chronic lymphocytic leukemia (B-CLL) is low in comparison to other B-cell lymph...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190210178

    authors: Perz J,Topaly J,Fruehauf S,Hensel M,Ho AD

    更新日期:2002-01-01 00:00:00

  • Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.

    abstract::Blinatumomab is a member of a novel class of T cell-engaging bispecific antibodies, so-called Bispecific T cell Engager (BiTEs). It is directed against the B cell differentiation antigen CD19 and intended for treatment of B cell malignancies. In clinical phase I/II trials, blinatumomab showed remarkable single-agent a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2016.1161185

    authors: Goebeler ME,Bargou R

    更新日期:2016-05-01 00:00:00

  • Concomitant primary polycythemia vera and follicle center cell non-Hodgkin lymphoma: a case report and review of the literature.

    abstract::The association of myeloproliferative and lymphoproliferative disorders is well known after cytotoxic drug or radiation exposure, while it is remarkably rare prior to therapy. We report on a patient simultaneously diagnosed as having polycythemia vera and II3A follicle center cell non-Hodgkin lymphoma (grade 1). At th...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/1042819021000016113

    authors: Rizzi R,Liso A,Pannunzio A,Carluccio P,Specchia G,Liso V

    更新日期:2002-11-01 00:00:00

  • Autologous Bone-Marrow Transplantation in Acute Lymphoblastic Leukaemia: 1980-89.

    abstract::The outcome of conventional therapy in adult acute lymphoblastic leukaemia (ALL) is disappointing. Allogeneic bone-marrow transplantation may give improved results but has only limited applicability because of the lack of a suitable donor in most patients. We have therefore investigated intensive chemotherapy and chem...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199009042474

    authors: Mcmillan AK,Gribben JG,Linch DC,Anderson C,Richards JD,Goldstone AH

    更新日期:1990-01-01 00:00:00

  • Involvement of miR17 pathway in glucocorticoid-induced cell death in pediatric acute lymphoblastic leukemia.

    abstract::Analysis of the microRNA transcriptome following dexa- methasone treatment of the acute lymphocytic leukemia (ALL) cell line RS4;11 showed a global down-regulation of microRNA levels. MIR17HG was rapidly down-regulated following treatment, with chromatin immunoprecipitation (ChIP) analysis demonstrating the promoter t...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.678004

    authors: Harada M,Pokrovskaja-Tamm K,Söderhäll S,Heyman M,Grander D,Corcoran M

    更新日期:2012-10-01 00:00:00

  • Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey.

    abstract::Next-generation sequencing (NGS) is increasingly employed for diagnosis, risk stratification, and management of patients with myelodysplastic syndrome (MDS). We aimed to describe beliefs and practice patterns among providers who treat MDS patients with respect to the utility of NGS in diagnosis, risk stratification, p...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1723013

    authors: Pine AB,Chokr N,Stahl M,Steensma DP,Sekeres MA,Litzow MR,Luger SM,Stone RM,Greenberg PL,Bejar R,Bewersdorf JP,Gore SD,Zeidan AM

    更新日期:2020-06-01 00:00:00

  • Selinexor for advanced hematologic malignancies.

    abstract::Recent measures to classify novel molecular targets with therapeutic potential across multiple hematologic tumors have identified the eukaryotic nuclear exporter, exportin 1 (XPO1), as a promising candidate. Molecular agents termed 'Selective Inhibitors of Nuclear Export' (SINEs) have been developed to selectively inh...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1775210

    authors: Walker JS,Garzon R,Lapalombella R

    更新日期:2020-10-01 00:00:00

  • Characteristics and outcome of acute myeloid leukemia in patients with a prior history of autoimmune disease.

    abstract::Although associations between autoimmune disorders (AIs) and the development of myeloid neoplasms have been described, the pathologic features and natural history of these malignancies have not been well characterized. We evaluated whether patients with AIs with acute myeloid leukemia (AML) were similar in nature to p...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.736982

    authors: DiNardo CD,Ogdie A,Hexner EO,Frey NV,Loren AW,Luger SM

    更新日期:2013-06-01 00:00:00

  • Coping styles, health status and advance care planning in patients with hematologic malignancies.

    abstract::This study evaluated whether measures of psychological well-being, including coping style, are associated with advance care planning (ACP). Data were from the Hematology Communications Study (HEMA-COMM), a prospective observational study of physician-patient communication in patients with hematologic malignancies. ACP...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2011.601474

    authors: Loberiza FR Jr,Swore-Fletcher BA,Block SD,Back AL,Goldman RE,Tulsky JA,Lee SJ

    更新日期:2011-12-01 00:00:00

  • Ultrastructural features of CD34+ hematopoietic progenitor cells from bone marrow, peripheral blood and umbilical cord blood.

    abstract::Hematopoietic progenitor cells from different sources have been widely characterized, but their ultrastructural morphology has never been described in detail. In this study, imunomagnetically separated CD34+ cells from normal bone marrow (BM), mobilized peripheral blood (PBSC) and human umbilical cord blood (CB) were ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190109099332

    authors: Deliliers GL,Caneva L,Fumiatti R,Servida F,Rebulla P,Lecchi L,De Harven E,Soligo D

    更新日期:2001-08-01 00:00:00

  • Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions.

    abstract::The anemia of MDS often results in decreased quality of life, which is invoked to justify red cell transfusions; however, there are sparse data regarding the minimum hemoglobin (Hb) at which it is safe to forgo transfusions for patients with no evidence of end-organ damage. This issue is even more important in the COV...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1791854

    authors: Tanasijevic AM,Revette A,Klepin HD,Zeidan A,Townsley D,DiNardo CD,Sebert M,DeZern AE,Stone RM,Magnavita ES,Chen R,Sekeres MA,Abel GA

    更新日期:2020-12-01 00:00:00

  • Analysis of HTLV-I in Hodgkin's Disease.

    abstract::Both Epstein-Barr virus (EBV) and the human T-cell leukemia virus I (HTLV-I) have been implicated in the generation of human lymphoproliferative disorders such as Burkitt's lymphoma, Hodgkin's disease (HD) and acute T-cell leukemia (ATL). In Hodgkin's disease EBV has been recently detected in Hodgkin's and Sternberg-R...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199109068088

    authors: Tesch H,Jücker M,Krönke M,Diehl V

    更新日期:1991-01-01 00:00:00

  • Clinicopathological analysis of follicular lymphoma with a polyploid karyotype.

    abstract::The prognostic significance of specific cytogenetic abnormalities in follicular lymphoma (FL) is an area of ongoing research. A small percentage of FL are characterized by a polyploid karyotype. Several studies have analyzed ploidy level to determine its role as an independent prognostic factor in non-Hodgkins lymphom...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199809092694

    authors: James GK,Horsman D,Connors JM,Klasa R,Wilson K,Argatoff L,Gascoyne RD

    更新日期:1998-01-01 00:00:00

  • Prognostic Features in the Myelodysplastic Syndromes: Importance of Morphological Atypia in the Marrow Cell Lineages.

    abstract::In order to clarify the relationship between myelodysplastic morphologic features of marrow cells and prognoses and 1.0 define other prognostic factors, 124 patients with the FAB criteria of myelodysplastic syndrome (MIX) were analysed. These included 57 patients with refractory anemia (RA), 5 RA with ring sideroblast...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199009042471

    authors: Takahashi M,Koike T,Kishi K,Moriyama Y,Hayashi S,Shibata A

    更新日期:1990-01-01 00:00:00

  • The anti-leukemic and lipid lowering effects of imatinib are not hindered by statins in CML: a retrospective clinical study and in vitro assessment of lipid-genes transcription.

    abstract::Imatinib, which has revolutionized chronic myeloid leukemia (CML) treatment, was suggested to improve lipid profile. Statins, a dyslipidemia drug, were reported to potentiate imatinib's antileukemic effect. However, analysis of imatinib combined with statins is lacking. We have retrospectively analyzed the normalizati...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2016.1228928

    authors: Ellis M,Krashin E,Hamburger-Avnery O,Gan S,Elis A,Ashur-Fabian O

    更新日期:2017-05-01 00:00:00

  • Contribution of flow cytometry to the diagnosis of malignant and non malignant conditions in lymph node biopsies.

    abstract::In order to assess the contribution of FC to the diagnosis of lymph node disorders we retrospectively compared the pathological and the FC diagnosis made in 118 consecutive lymph node biopsies. Pathological diagnosis included non malignant conditions (n = 43), B-cell Non Hodgkin lymphoma (NHL) (n = 30), T-cell NHL (1 ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190310001609906

    authors: Ravoet C,Demartin S,Gerard R,Dehon M,Peny MO,Petit B,Delannoy A,Husson B

    更新日期:2004-08-01 00:00:00

  • Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis.

    abstract::The recurring translocation t(1;19) (q23;p13) with TCF3-PBX1 rearrangements are uncommon in adult acute lymphoblastic leukemia (ALL), and their prognostic impact remains to be described in the era of modern chemotherapies. We investigated 427 adult patients with newly diagnosed pre-B ALL, 16 (4%) had t(1;19)(q23;p13) ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1824071

    authors: Yilmaz M,Kantarjian HM,Toruner G,Yin CC,Kanagal-Shamanna R,Cortes JE,Issa G,Short NJ,Khoury JD,Garcia-Manero G,Ravandi F,Kadia T,Konopleva M,Wierda WG,Jain N,Estrov Z,Sasaki K,Pierce S,O'Brien SM,Jabbour EJ

    更新日期:2021-01-01 00:00:00

  • Prevalence of hepatitis C infection in patients with non-Hodgkin's lymphoma in South Florida and review of the literature.

    abstract::The etiology of non-Hodgkin's lymphoma is unknown in the majority of the cases. Although Epstein-Barr virus, human T-cell leukemia-lymphoma virus and human herpes virus-8 have been established as casual agents in the pathogenesis of specific types of lymphoma, the role of hepatitis C virus (HCV) in lymphomagenesis rem...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190400007771

    authors: Morgensztern D,Rosado M,Silva O,Santos E,Abdullah S,Goodman M,Hamilton-Nelson K,Rosenblatt J,Lossos I

    更新日期:2004-12-01 00:00:00

  • Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence.

    abstract::Ruxolitinib is the only therapy with an approved indication for myelofibrosis (MF), a myeloproliferative neoplasm associated with progressive bone marrow fibrosis and extramedullary hematopoiesis. Although the pivotal phase 3 COMFORT studies included only patients with intermediate-2 or high-risk MF, the US indication...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2016.1195501

    authors: Harrison CN,Talpaz M,Mead AJ

    更新日期:2016-10-01 00:00:00

  • Pro-survival role of protein kinase C epsilon in Philadelphia chromosome positive acute leukemia.

    abstract::Durable responses to imatinib monotherapy are rarely seen in aggressive forms of Philadelphia chromosome positive (Ph+) leukemias. To investigate the possible cause of treatment failure we examined the role of protein kinase C epsilon (PKCE), an oncogene highly implicated in the development of solid tumors and resista...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1043545

    authors: Loi TH,Dai P,Carlin S,Melo JV,Ma DDF

    更新日期:2016-02-01 00:00:00

  • The Splenic White Pulp in Chronic Lymphocytic Leukaemia: A Microenvironment Associated with CR2 (CD21) Expression, Cell Transformation and Proliferation.

    abstract::Splenectomy specimens from 8 cases of chronic lymphocytic leukaemia (CLL) were examined. The infiltrate in the red pulp consisted predominantly of small lymphocytes. In contrast the predominant cells in the white pulp were pro-lymphocytes and para-immunoblasts. The Ki67 marker, which identifies cells in growth phase, ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428199009169601

    authors: Lampert IA,Hegde U,Van Noorden S

    更新日期:1990-01-01 00:00:00

  • Hepatitis C virus, B-cell proliferation and lymphomas.

    abstract::Accumulating evidence support a role for hepatitis C virus (HCV) in the pathogenesis of human lymphoproliferative disorders. Clonal expansions of B lymphocytes have been prevalently detected in the bone marrow, in the liver and in the peripheral blood of HCV-infected patients. Epidemiologic studies have associated HCV...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190290016845

    authors: Gasparotto D,De Re V,Boiocchi M

    更新日期:2002-04-01 00:00:00

  • Histopathology and Immunocytochemistry of Lymph Node Biopsies in Chronic Lymphocytic Leukemia and Immunocytoma.

    abstract::When lymph node biopsies of lymphocytic neoplasms are studied with subtle morphological and immunohistochemical methods meaningful information is obtained, that is not only of theoretical value, but which also relates to the clinical behavior ("leukemia," paraproteinemia, prognosis). Such an analysis allows us to diff...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199109103399

    authors: Lennert K,Tamm I,Wacker HH

    更新日期:1991-01-01 00:00:00

  • Fulminant bilateral cerebellar syndrome in a patient with chronic lymphocytic leukemia.

    abstract::A 55 year old patient with chronic lymphocytic leukemia (CLL) and long-standing excessive lymphocytosis developed a rapidly progressive neurological syndrome. Differential diagnosis focused on two rate neurological complications in this disease: direct brain infiltration by leukemic cells versus progressive multifocal...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199409049756

    authors: Quitt M,Bazac I,Gross B,Aghai E

    更新日期:1994-11-01 00:00:00

  • The impact of early molecular response in children and adolescents with chronic myeloid leukemia treated with imatinib: a single-center study from China.

    abstract::Chronic myeloid leukemia (CML) is rare among children and adolescents. The early molecular response (EMR) is an important prognostic significance for adult CML patients. This study explored the impact of EMR on the prognosis in 40 children and adolescents with CML-CP treated with imatinib (IM). Our results showed that...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2017.1422860

    authors: Shao H,Zeng Z,Cen J,Zhang J,Bai S,Wu C,Gong Y,Wang Y,Qiu H,Chen S,Pan J

    更新日期:2018-09-01 00:00:00

  • The emerging role of immune checkpoint based approaches in AML and MDS.

    abstract::The development of immune checkpoint inhibitors represents a major breakthrough in the field of cancer therapeutics. Pursuant to their success in melanoma and numerous solid tumor malignancies, these agents are being investigated in hematological malignancies including acute myelogenous leukemia (AML) and myelodysplas...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2017.1344905

    authors: Boddu P,Kantarjian H,Garcia-Manero G,Allison J,Sharma P,Daver N

    更新日期:2018-04-01 00:00:00

  • Presentation and outcomes among patients with isolated myeloid sarcoma: a Surveillance, Epidemiology, and End Results database analysis.

    abstract::Isolated myeloid sarcoma (MS) is a rare extramedullary presentation of acute myeloid leukemia (AML). Little is known about MS outcomes due to its rarity. A population-based analysis of MS using the Survival, Epidemiology, and End Results (SEER) database was performed. We identified 345 patients, aged 15 or older, diag...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2014.963080

    authors: Movassaghian M,Brunner AM,Blonquist TM,Sadrzadeh H,Bhatia A,Perry AM,Attar EC,Amrein PC,Ballen KK,Neuberg DS,Fathi AT

    更新日期:2015-06-01 00:00:00

  • Monokine induced by interferon gamma (MIG/CXCL9) is an independent prognostic factor in newly diagnosed myeloma.

    abstract::Immune suppression is a hallmark of multiple myeloma (MM), but data on soluble factors involved in the fate of immune effector cells are limited. The CXCR3-binding chemokine monokine induced by interferon-gamma (MIG/CXCL9) has been associated with tumor progression, immune escape, and angiogenesis in several malignanc...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2016.1151511

    authors: Bolomsky A,Schreder M,Hübl W,Zojer N,Hilbe W,Ludwig H

    更新日期:2016-11-01 00:00:00

  • Tertiary center referral patterns for patients with myelodysplastic syndrome are indicative of age and race disparities: a single-institution experience.

    abstract::Little is known about disparities in myelodysplastic syndromes (MDS). We performed a retrospective chart review of patients with MDS (n = 252) evaluated at the University of Maryland Greenebaum Cancer Center between 2000 and 2010. The median age at diagnosis was 65 years, which was lower than the median age of 76 year...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.710904

    authors: Zandberg DP,Hendrick F,Vannorsdall E,Bierenbaum J,Tidwell ML,Ning Y,Zhao XF,Davidoff AJ,Baer MR

    更新日期:2013-02-01 00:00:00

  • Transplant of ex vivo incubated bone marrow with rIL -7 for the enhancement of immuno-hematopoietic reconstitution.

    abstract::Interleukin-7 (IL-7) is a critical cytokine in early B and T cell development. Peripheral T cell expansion and thymopoiesis and is a result of the ongoing reconstitution from uncommitted stem cells after transplant. We investigated the efficacy of ex vivo incubated bone marrow cells treated with recombinant human IL-7...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1016935

    authors: Abdul-Hai A,Ben Yehuda A,Slavin S,Or R

    更新日期:2015-01-01 00:00:00